A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above

Clinical trial NCT05559476 · COMPLETED

Trial details

NCT number: NCT05559476
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Respiratory Syncytial Virus Infections

Start date: 2022-10-20
Primary completion: 2023-03-07
Enrollment: 1029

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.